Chorea …

Movement Disorders

Updated 06.06.2023
Released 08.05.1994
Expires For CME 06.06.2026

Chorea

Authors: Serena Wong MD, Robert Fekete MD

See Contributor Disclosures

Chorea

In This Article

Quick Link

Introduction

Overview

Chorea, derived from the Latin choreus meaning "dance," describes a syndrome characterized by irregular, hyperkinetic, involuntary movements resulting from a continuous flow of random muscle contractions. Athetosis refers to the writhing, slow, and irregular movements involving the hand and fingers. Choreoathetosis is the term to describe chorea with a writhing quality. When chorea is mild, it is difficult to differentiate from restlessness. Proximal flinging movements are referred to as ballism. Although the mechanism is not completely understood, chorea is thought to result from the imbalance in the direct and indirect pathways in the basal ganglia circuitry (14). Primary chorea is either idiopathic or hereditary. Secondary chorea is related to autoimmune, vascular, infectious, pharmacologic, and metabolic disorders. The author aims to provide an up-to-date discussion of the clinical presentations, etiology, pathogenesis, differential diagnosis, and management of this order.

Key points

	• The etiology of chorea includes genetic, idiopathic, autoimmune, pharmacological, metabolic, and structural lesions.
	• Vascular disease of the brain is the most common cause of nongenetic chorea in adults.
	• Treatment for chorea is based on reversing the underlying cause of chorea, if feasible.
	• Antiepileptics and antipsychotics are the mainstay therapy to achieve symptomatic control of chorea, regardless of the underlying etiology. Dopamine depletion achieved by inhibition of vesicular monoamine transporter-2 (VMAT2) has been used to treat patients with Huntington disease, tardive dyskinesia, and other movement disorders.

Clinical manifestations

Presentation and course

Primary chorea

Huntington disease. Huntington disease (HD) is a progressive neurodegenerative disease. It is an autosomal dominant disorder caused by a CAG trinucleotide repeat expansion in a gene on chromosome 4p16.3. A repeat of 36 CAG or more can lead to the disease. The age of onset decreases with longer CAG repeats. The mutated Huntingtin protein in Huntington disease impaired neural progenitor cell division and neuronal migration and maturation, leading to underdevelopment of the cortex in Huntington disease mice (105). The expanded repeat is unstable and tends to increase in the subsequent generation, a phenomenon called anticipation. A systematic review was conducted to estimate the prevalence of Huntington disease in the postdiagnostic testing era (1993 to 2015); the prevalence of Huntington disease is significantly lower in Asian populations compared to western Europe, North America, and Australia (133). Huntington disease is characterized by a triad of choleric movements (facial grimacing and writhing limb movements), dementia, and behavioral disturbances including personality changes, depression, as well as psychosis (129). In general, the age of onset is approximately 40 years. Approximately 5% of the affected individuals have a juvenile onset under the age of 20, and about 30% are diagnosed with Huntington disease at the age of 50 or above. In juvenile onset cases, rigidity, hypokinesia and dystonia are common. Other common motor manifestations in Huntington disease include slowing of saccades, myoclonus, rigidity, and ataxia (91). Dystonia is usually observed in the advanced stage of Huntington disease or is associated with the use of dopaminergic medications. Dysphagia and aspiration tend to occur in the terminal stage of the disease; however, cortical language is usually spared.

Adenylate cyclase 5 mutation. Mutations of adenylate cyclase 5 (ADCY5) have emerged as an important causal gene for early-onset autosomal dominant chorea and dystonia (19; 24). Although ADCY5 mutations have been initially mentioned as a phenocopy of Huntington disease, this is certainly not the case. The two conditions are easily distinguishable because juvenile Huntington disease is characterized by rigid-akinetic syndrome, cognitive decline, and occasional seizure disorder, but almost never chorea. In contrast, ADCY5 syndrome is characterized by delayed motor and speech milestones, episodic axial hypotonia, ataxia, generalized chorea and dystonia, myoclonus, and myopathy-like facial appearance. The disorder is frequently misdiagnosed as dyskinetic cerebral palsy (106). Nevertheless, as often happens with newly described genetic conditions, there is growing evidence pointing towards the great genetic and phenotypic variability of ADCY5 mutations: autosomal recessive mutations and a wide range of hyperkinetic movement disorders including chorea, dystonia, myoclonus, and tics (15).

Phosphodiesterase 10A mutation. Phosphodiesterase 10A (PDE10A) mutation is another genetic disorder that causes an early onset chorea. The phenotype can be similar to the one seen in the ADCY5 disease. Interestingly, both mutations are associated with same changes in the basal ganglia, including decreased PDE10A expression in the striatum and globus pallidus (109). There is also a description of a homozygous loss-of-function mutation in PDE2A associated with an early onset hereditary chorea (134).

Neuroferritinopathy. Neuroferritinopathy is an autosomal dominant condition causing chorea (50%), dystonia (42.5%) and, less often, parkinsonism (7%). It is caused by mutations in the ferritin light chain gene, resulting in iron deposition and cavitation in the basal ganglia on brain MRI (102).

Chorea acanthocytosis. Chorea acanthocytosis (ChAc) is a rare neurodegenerative disease that can be transmitted by autosomal recessive, dominant, or X-linked inheritance. It is a part of the group of neuroacanthocytosis syndrome consisting of McLeod syndrome, Huntington disease-like syndrome 2, and pantothenate kinase-associated neurodegeneration. The clinical manifestation includes orofacial dyskinesia, chorea, and peripheral neuropathy. Epilepsy and parkinsonism can sometimes be seen in patients with chorea acanthocytosis. Behavioral problems such as depression, obsessions, compulsions, self-mutilation, and psychotic disorders are commonly seen in chorea acanthocytosis (151). In clinical practice, obsessions and compulsions are often more disabling herein than in Huntington disease. In both Huntington disease and chorea acanthocytosis, the muscle tone is increased, and with progression of the illness, there is a tendency for worsening of the rigidity and a decrease of the severity of the chorea. According to a multicenter retrospective analysis, GPi-DBS provides long-lasting improvement in patients with chorea acanthocytosis. A study reported the efficacy of the use of STN-DBS in two siblings with severe oromandibular dystonia and gait abnormalities (156). Further research is needed to improve the understanding of the mechanisms and the treatment modalities for chorea acanthocytosis.

Dentatorubralpallidoluysian atrophy. Dentatorubralpallidoluysian atrophy (DRPLA) is an autosomal dominant disorder caused by a CAG trineucleotide repeat expansion in chromosome 12 (73). The function of the mutant protein, Atrophin-1, is unknown. Individuals with 53 or more CAG repeats develop the symptoms. Clinical manifestation of this disease includes chorea, myoclonus, ataxia, epilepsy, and cognitive decline. Neuroimaging studies demonstrated atrophy of the cerebellum, tegmentum, and cerebral hemispheres with ventricular dilatation (14). Neuronal loss and gliosis in the dentate nucleus, red nucleus, globus pallidus, and subthalamic nucleus is often seen pathologically (14).

Benign hereditary chorea. Patients with benign hereditary chorea, an autosomal dominant illness, have a mutation in the TITF1/NKX2-1 gene, which codes for a transcription factor essential for the organogenesis of the lung, thyroid, and basal ganglia (84; 71). In fact, the clinical picture of these patients is characterized by a variable combination of chorea, mental retardation, congenital hypothyroidism, and chronic lung disease; hence, the term brain-thyroid-lung syndrome has been proposed for this disease (154; 45). Studies with clinical-genetic correlation have helped to demonstrate that the clinical spectrum of benign hereditary chorea is wider than previously thought, including dystonia, myoclonus, restless legs syndrome, psychosis, hypotonia, seizures, joint laxity, neonatal respiratory failure, pituitary involvement, and short stature (03; 83; 57; 67; 119; 68). It has also been demonstrated that the phenotype of benign hereditary chorea and hypothyroidism can be caused by distinct NKX2-1 mutations (51; 123; 71). A description of 28 patients from France harboring TITF1/NKX2-1 gene mutations confirms that a gamut of movement disorders and nonmotor features are associated with benign hereditary chorea: hypotonia and chorea were present in early infancy, with delayed walking ability (25 out of 28); dystonia, myoclonus, and tics were often associated; and attention deficit hyperactivity disorder was present in seven (58). In summary, the clinical presentation of NKX2-1 mutations is heterogeneous, often including severely disabling features. Few patients with this condition who underwent PET imaging to study postsynaptic nigro-striatal dopamine receptors were found to have decreased density of receptors (85).

Secondary chorea

Immune-mediated chorea. Sydenham chorea is a hyperkinetic disorder characterized by involuntary, irregular, jerky movements involving more than one region of the body. It is a common form of acquired childhood chorea (159). The typical age of onset is 5 to 15 years with a female gender predominance (43). The first episode of Sydenham chorea typically occurs 6 to 8 weeks poststreptococcal infection (11). Sydenham chorea is one of the major diagnostic criteria of rheumatic fever and is caused by a group A beta-hemolytic Streptococcus infection. The diagnosis of Sydenham chorea is clinical and can be confirmed by elevated erythrocyte sedimentation rate or the anti-streptolysin-O (ASLO) and anti-DNAse B titers (115). Neuropsychiatric symptoms are highly prevalent in Sydenham chorea, including major depression, generalized anxiety disorder, social phobia, and obsessive-compulsive disorder, and may persist even after the improvement of motor symptoms. In addition, other neurologic manifestations associated with Sydenham chorea are dysarthria, dysgraphia, lingual dystonia, muscle weakness, and dysphagia.

Multiple neuronal antibodies, including anti-glutamic acid decarboxylase 65 (anti-GAD 65), contactin-associated protein-like 2 (CASPR2), leucine-rich glioma-inactivated 1 protein (LGI1), and voltage-gated calcium channel antibody (VGCC) are associated with nonparaneoplastic antibody-positive chorea. High-titer GAD-65 antibody is associated with stiff person spectrum disorder, which is characterized by truncal and proximal limb stiffness, hyperlordosis, and painful episodic spasm triggered by tactile or auditory stimuli (39). Progressive encephalomyelitis with rigidity and myoclonus (PERM) is an atypical form of stiff person spectrum disorder (07). LGI1 and CASPR2 are associated proteins of voltage-gated potassium channels. The clinical features of LGI1 antibody encephalitis include memory impairment, faciobrachial dystonic seizure, and hyponatremia. Faciobrachial dystonic seizure is characterized by brief (1 to 3 sec), frequent, stereotypical, and focal movements of the arm and ipsilateral face or arm (55). In contrast, the clinical manifestation of CASPR2 antibody is much more diverse and can affect both central and peripheral nervous systems. CASPR2 antibody is associated with peripheral nerve hyperexcitability syndromes, including cramp fasciculation syndrome, Isaacs syndrome, and Morvan syndrome (136). All of these can lead to muscle twitching and muscle cramps.

N-methyl-D-aspartate receptor (NMDA-R) encephalitis is the most common sporadic autoimmune encephalitis in children and younger adults. There is a female predominance (48; 89). Interestingly, it can be paraneoplastic, postinfectious, or idiopathic in etiology. Ovarian teratomas are found in half of the cases of adult women, whereas one third of the cases are identified in teenage females (89). Patients with this disease can experience neuropsychiatric symptoms characterized by psychosis, catatonia, and disinhibition as well as various motor disorders, including limb dyskinesia/chorea, orofacial dyskinesia, ataxia, and dystonia (48). Some patients are diagnosed with NMDA-R encephalitis after HSV encephalitis, typically 1 to 4 weeks after initial infection (48; 89).

Anti-IgLON5 disease is a recently discovered neurodegenerative disorder associated with antibodies against the neuronal cell adhesion protein, IgLON5, of unknown function (54). The four main symptoms in patients with this disorder include REM and non-REM parasomnias, bulbar syndromes, cognitive decline, and movement disorders. A retrospective, observational study demonstrated that the first signs and symptoms of this disease were abnormal movements (53). Gait and balance disturbance is the most frequent complaint, followed by chorea, bradykinesia, abnormal body postures or rigidity, and tremors. About one-third of the participants in the study also reported other hyperkinetic movements including myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias. The craniofacial dyskinesias were frequently associated with concurrent abnormal movements. The constellation of multiple movement disorders, sleep alternations, bulbar symptoms, and cognitive impairment should alert clinicians to consider this disease.

Systemic lupus erythematosus and primary antiphospholipid syndrome are rare causes of chorea and occur in 1% to 2% of all cases (05). Neuropsychiatric symptoms are more common than movement disorders in systemic lupus erythematosus, but chorea is the most common movement disorder. The typical age of onset is between 15 and 26 years, with a female predominance.

Vascular chorea. Hemichorea can occur contralateral to the lesion in the basal ganglia, thalamus, or lentiform nucleus after stroke (30). When a lesion involves the subthalamic nucleus, hemichorea occurs ipsilateral to the lesion.

Polycythemia vera (PV) is a myeloproliferative neoplasm associated with erythrocytosis. A diagnosis of polycythemia vera is made when an individual has hemoglobin greater than 16.5 g/dL (greater than 16.0 g/dL in women) or hematocrit greater than 49% (greater than 48% in women), or increased red cell mass, hypercellularity in bone marrow biopsy, and presence of the JAK2 mutation (13). In addition, chorea can occur after a stroke, especially when the subthalamic nucleus is involved.

Infectious chorea. Chorea can occur as an acute manifestation of bacterial, viral, aseptic, or tuberculous encephalitis and meningitis. Various movement orders have been observed in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Ataxia and myoclonus are the most common manifestations; however, chorea, parkinsonism, and dystonia have also been reported (137).

Drug-induced chorea. Acute chorea can be caused multiple drugs including dopamine agonists, stimulants (eg, cocaine and amphetamines), levodopa therapy, oral contraceptives, and anticonvulsants (eg, carbamazepine, valproate, phenytoin, and gabapentin) (70). Tardive dyskinesia is a movement disorder characterized by irregular bucco-oral movements after prolonged use of antipsychotics, especially the first-generation antipsychotic medications.

Metabolic causes for chorea. Chorea and hemichorea have been reported as the initial presenting symptoms in the setting of hypoglycemia and nonketotic hyperglycemia (128; 59; 96).

Prognosis and complications

Prognosis depends on etiology. Drug-induced chorea is usually reversible after the medication is discontinued, but persistent as a tardive syndrome following prolonged use of antipsychotic medications. Vascular chorea-hemiballism following lacunar stroke is dramatic at the onset, but its severity spontaneously declines with time in most patients. Most choreas may be treated with medication to reduce symptom intensity, although some, such as powerful persistent chorea-hemiballism, may be refractory to all but aggressive intervention (eg, thalamotomy, pallidotomy). Classically, Sydenham chorea resolves in 1 to 6 months. There is evidence that patients who had Sydenham chorea in the past are often left with frontal lobe dysfunction, such as dysexecutive syndrome, as well as attention deficit disorder (10; 26). Harsanyi and colleagues not only replicated the findings of patients with Sydenham chorea who performed worse than healthy controls in tasks of phonemic and semantic verbal fluency but also showed that they had a poorer performance on the Token test, which assesses verbal comprehension (61). Interestingly, individuals with rheumatic fever without chorea also had a significantly worse verbal fluency (61). Huntington disease, neuroacanthocytosis, and other degenerative illnesses have poor prognoses, dependent more on the underlying condition than on the choreic movements, with inexorable progression leading to death. A review of 52 individuals with chorea-acanthocytosis found that the mean disease duration from diagnosis was 11 years, whereas patients with McLeod syndrome, another cause of neuroacanthocytosis, had a much longer survival of 21 years. The most common causes of death were pneumonia, cardiac disease, seizure, suicide, and sepsis. Of note, suicide accounted for 10% of deaths in subjects with chorea-acanthocytosis (150).

Biological basis

Etiology and pathogenesis

The causes of chorea, as listed in the section under differential diagnosis and summarized in Table 1, are many. In addition to the classical presentation, chorea is also found in less widely recognized settings. For instance, in a review of the phenomenology of 100 patients with focal motor seizures, a group of experts identified chorea in 4% of these individuals (49). The etiology also depends on the age at onset. For instance, in adults, vascular chorea is the most common etiology (127). In contrast, in children, Sydenham chorea account for more than 90% of the acute cases of chorea (159).

In all cases of chorea, it is assumed that there is disruption of basal ganglia modulation of thalamocortical motor pathways. This disruption may be due to structural damage, selective neuronal degeneration, neurotransmitter receptor blockade, or other metabolic factors within the basal ganglia. Structural lesions of the subthalamic nucleus or subthalamic region, caused by infarcts, hemorrhage, or tumors, produce chorea (94). Alterations in striatal neurotransmitters may occur endogenously, as in Huntington disease; or exogenously, as seen with drug use or withdrawal (122; 99; 08).

In Huntington disease, mutant Huntingtin (mHTT) protein, an intracellular protein, was found to be transiently increased in the cerebrospinal fluid after acute neurotoxic injury, suggesting the mutant protein was released from dying neurons into the extracellular space and then cerebrospinal fluid (25). mHTT protein in the cerebrospinal fluid correlates with disease burden as well as motor and cognitive performance (25). However, the cell type and brain region source of mHTT remains unclear, but striatum and cortex likely contribute to the pool mHTT in the cerebrospinal fluid given that these brain regions are most affected in Huntington disease.

The role of autoimmune processes in chorea is of growing interest. Antibasal ganglia antibodies have been detected in subjects with Sydenham chorea using ELISA and Western immunoblotting methods. The antibasal ganglia antibodies play a role in the development of chorea by disrupting corticostriate circuitry (31). It was demonstrated that these autoantibodies target neuronal tubulin (82). Interestingly, there are data suggesting that persistence of Sydenham chorea for 2 years or more is related to structural dysfunction rather than to an ongoing autoimmune process (144). A study, however, failed to induce behavioral changes in rodents infused with antibodies from patients with Sydenham chorea although they bound to neural cells (12). Nevertheless, studies provide compelling evidence that Streptococcus-induced antibodies cross-react with central dopamine receptors inducing movement disorders and behavioral abnormalities (41; 17; 46; 38). Autoimmune-mediated damage may be the result of small vessel occlusive disease in the basal ganglia or by direct antibody attack on neuronal antigens in the basal ganglia (79; 146).

In systemic lupus erythematosus, 90% of patients with chorea test positive for antiphospholipid antibodies (131). These patients also have circulating antibodies that bind to neuronal surface (41). Immunologic studies show that antiphospholipid antibodies associated with chorea target beta2-glycoprotein I cause thrombotic phenomena (124). Chorea may also be a component of paraneoplastic syndromes. Although rare, paraneoplastic chorea associated with small cell lung cancer, lymphoma, renal cell cancer, and cardiac fibroelastoma has been reported (35; 148; 16). Previous investigations suggested that paraneoplastic chorea was almost exclusively associated with CV2/CRMP5 related to small cell lung cancer or, less commonly, malignant thymoma or breast cancer (63; 56). Similar results were provided by a report of 13 subjects with paraneoplastic chorea who corresponded to 1.2% of a large, multinational European cohort of individuals with paraneoplastic syndromes and, after small cell lung cancer, the most common neoplasms were lymphoma, bowel, or kidney cancers (149). A series of 14 patients from the U.S., however, indicates that ANNA is an antibody also commonly associated with paraneoplastic chorea and most patients were found to have small cell carcinoma or adenocarcinoma (117).

The association between chorea and polycythemia vera was thought to be due to hyperviscosity in the basal ganglia, thereby causing chorea. However, some patients develop chorea without a particularly high hematocrit (88). In mice with quinolinic acid striatal lesions, inhibition of JAK2 led to reduced apoptosis and astrogliosis, suggesting that JAK2 inhibition is neuroprotective (66). It was postulated that the expression of JAK2 in the stratum may promote astrogliosis and inflammation in the basal ganglia, leading to chorea in the setting of JAK2 mutation without polycythemia vera.

Table 1 contains a list of a number of licit and illicit drugs that can cause chorea. Of note, in the context of patients with movement disorders, levodopa and other dopaminergic agents are a common cause of chorea in subjects with Parkinson disease. Antiepileptic agents have long been recognized as a cause of chorea, particularly in patients with structural brain lesions. There are reports relating valproate use to onset of chorea, which is surprising considering the established antichoreic action of this agent in Sydenham chorea (142; 147).

There are reports of causes of chorea in the adults or the elderly that, although rare, should be kept in mind by the clinician: acute bilateral basal ganglia lesions in patients with brainstem cavernous malformation, brainstem glioma, diabetic uremia, moyamoya disease, post-pump, valproic acid use, pontine hemorrhage and putaminal cavernous angioma (81; 95; 132; 147; 92; 90; 120; 158). There are reports describing that the damage of post-pump chorea may result in a clinical picture similar to progressive supranuclear palsy (118). It is interesting that although not often recognized as a cause of chorea, uremia can cause this movement disorder and lead to neuroimaging findings rather similar to what one sees in chorea associated with hyperglycemia. A study showed that there are differences between the two conditions on magnetic resonance imaging of the brain: the diabetic patients demonstrated T1-hyperintense and inhomogeneous lesions in the basal ganglia, whereas the others had T2-hyperintense and homogeneous lesions in this area (80).

Another rare cause of the combination of ataxia and chorea is mutation in the mitochondrial DNA polymerase gamma. In a report of a series of patients, the authors found a myriad of clinical features: chronic external ophthalmoplegia (100%), areflexia to the lower extremity (100%), impaired vibration sense (100%), bilateral ptosis (69%), epilepsy (38%), and hyperkinetic movement disorders, including chorea (31%), dystonia (31%), and myoclonus (23%) (143). There are also reports of unusual causes of chorea: extrapontine myelinolysis (110) and associated with intratumoral chemotherapy catheter (160), as well as induced by cerebrospinal fluid shunt (42).

The presence of chorea reflects striatal dysfunction, as seen in the classic chorea of Huntington disease or subthalamic dysfunction (34). Although many biological factors are associated with chorea, neuroanatomic data implicate the putamen, globus pallidus, and subthalamic nuclei as key structures in all choreic disorders (125). The brief involuntary movements are initiated via the motor outflow pathway from thalamocortical to corticospinal. Modulation of the thalamocortical output occurs via inhibition of the thalamic nuclei by the globus pallidus and subthalamic nuclei and the inhibitory neurotransmitter gamma-aminobutyric acid (02). Multiple neurotransmitters seem to play a role in the pathophysiology of chorea, most importantly dopamine (74). Once manifested clinically, no specific electrophysiologic features reliably discriminate chorea from normal movements or other involuntary movements (145). Electrophysiologic studies indicate that cortical modulation is normal in some forms of chorea, thus, confirming the subcortical origins of the involuntary movements (60). Etiologically diverse types of chorea are thought to reflect deficient globus pallidum internal inhibitory input to the motor thalamus resulting in excessive thalamocortical motor facilitation. However, there are also inconsistencies between the model and clinical evidence, including the abolition of drug-induced chorea in Parkinson disease through pallidotomy, which, according to the model, should lead to increased excitatory thalamocortical drive and, thus, worsening of chorea. Current views maintain that more complex changes in the temporal and spatial firing pattern of the globus pallidum internal underlie hyperkinetic movement disorders such as chorea (112; 104; 107). This has been challenged by studies suggesting that in both Sydenham chorea and chorea associated with Huntington disease there is an increase of inhibition in the motor cortex (77).

Differential diagnosis

Confusing conditions

The approach to diagnosis is guided by several factors, including the onset of symptoms, age, family history, and associated neurologic symptoms. In the setting of acute presentation, vascular etiology should be suspected. Sydenham chorea should be considered in children presenting with acute to subacute onset of chorea. Other etiologies with subacute onset of chorea include autoimmune diseases, metabolic derangement, and drugs. Chronic presentation should raise suspicion of genetic diseases, such as Huntington disease in adults and Wilson disease in children.

Table 1 lists both common and uncommon conditions associated with chorea. As mentioned in the Etiology section, the reader should consider age at onset when developing a plan for diagnostic evaluation. A review discusses the etiology of chorea in children (06).

Table 1. Conditions Associated with Chorea

Autoimmune causes
		• Paraneoplastic
				- CRMP-5 (CV2) - ANNA-1 (Hu) - NMDAR - ANNA-2 (Ri) - CASPR2 - PDE-10A
		• Systemic disease
				- SLE - PAPS
		• Idiopathic
				- NMDAR - GAD-65 - CASPR2 - LGI1 - IgLON5
Genetic causes
	• Ataxia-telangiectasia • Ataxia associated with oculomotor apraxia • Benign hereditary chorea • C9orf72 expansions • Dentatorubropallidoluysian degeneration • Friedreich ataxia • Glucose transporter deficiency • Huntington disease • Huntington disease-like illnesses • Leigh disease and other mitochondriopathies • Lesch-Nyhan disease • McLeod syndrome • Neuroacanthocytosis • Neuroferritinopathy • Pantothenate kinase associated degeneration • POLG mutation • Prion disease • PRRT2 gene mutation • Spinocerebellar atrophy type 2 • Spinocerebellar atrophy type 3 • Spinocerebellar atrophy type 17 • Tuberous sclerosis • Xeroderma pigmentosum • Wilson disease
Drug-related
	• Amantadine • Amphetamine • Anticonvulsants • Antihistamine agents • Carbon monoxide • CNS stimulants (methylphenidate, pemoline, cyproheptadine) • Cocaine • Dopamine agonists • Dopamine-receptor blockers • Ethanol • Levodopa • Levofloxacin • Lithium • Sympathomimetics • Theophylline • Tricyclic antidepressants • Valproic acid • Withdrawal emergent syndrome
Infections
	• AIDS related (toxoplasmosis, progressive multifocal leukoencephalopathy, HIV encephalitis) • Bacteria
			- Diphtheria - Scarlet fever - Whooping cough
	• Virus
			- B19 parvovirus - Herpes-6 virus encephalitis - Influenza encephalitis - Japanese encephalitis - Measles - Mumps - HIV - West Nile River encephalitis - SARS-CoV-2
	• Parasites
			- Neurocysticercosis
	• Protozoan
			- Malaria - Syphilis
Endocrine-metabolic dysfunction
	• Adrenal insufficiency • Hyper/hypocalcemia • Hyper/hypoglycemia • Hypomagnesemia • Hypernatremia • Liver failure • Uremia
Vascular
	• Polycythemia vera • Postpump chorea (cardiac surgery) • Posterior reversible encephalopathy syndrome • Stroke • Subdural hematoma
Miscellaneous
	• Anoxic encephalopathy • Brainstem cavernous malformation • Brainstem glioma • Cerebral palsy • Cerebrospinal fluid shunt-induced • Extrapontine myelinolysis • Intratumoral chemotherapy catheter • Kernicterus • Multiple sclerosis • Normal maturation (less than 12 months old) • Nutritional (eg, B12 deficiency) • Pontine hemorrhage • Posttraumatic (brain injury) • Putaminal cavernous malformation

Diagnostic workup

Children and adults with chorea should undergo diagnostic evaluation, which includes neuroimaging and laboratory study. A thorough medical history including current and past medications and family and social history will help refine the differential diagnosis. MRI is preferable to CT due to the superior delineation of the subcortical tissue usually involved. Table 2 outlines the basic testing recommended. Further studies should be undertaken when clinical factors warrant. These might include genetic testing for Huntington disease or Huntington disease phenocopies, benign hereditary chorea, and other less common causes of genetic chorea and HIV antibody testing (126), muscle biopsy for mitochondrial disease, cerebrospinal fluid analysis for inflammation, drug or toxin assays, and peripheral blood smear with 1:1 saline dilution for acanthocytes and amino acid measurements. The genetic test for Huntington disease should be considered even for patients without a suggestive family history. A de novo expansion of the unstable triplet CAG repeat occurs in approximately 3% of affected patients (140). Because diabetes mellitus can cause chorea in adults, appropriate studies should always be ordered (28). Paraneoplastic antibody studies should also be considered in patients with new-onset unexplained chorea (148). Functional neuroimaging studies show that patients with chorea associated with diabetes have evidence of presynaptic nigrostriatal dysfunction on SPECT (135), and there is hypometabolism of the basal ganglia in chorea-acanthocytosis (37).

Table 2. Initial Laboratory Investigation of Chorea

• Antinuclear antibody
• Antineuronal antibodies
• Antiphospholipid antibodies
• Antistreptolysin O titers
• Brain MRI
• Complete blood count
• Ceruloplasmin
• Comprehensive metabolic panel, including tests for diabetes mellitus type II
• Thyroid hormone assay (TSH, T4)
• Urine toxicologic screen for drugs of abuse

Management

The most important principle of management of chorea is to remove the cause. This is possible in drug-induced chorea, metabolic or endocrine chorea, and to some extent even in immunologic chorea, such as Sydenham chorea, with penicillin prophylaxis. Unfortunately, in most choreic syndromes encountered in clinical practice causal therapies are not available and symptomatic treatment is required.

Dopamine depletors or receptor blockers are the mainstay of pharmacological treatment of chorea regardless of the etiology. As a rule, the more D2 receptor blocking action, the greater the antichoreic efficacy. Although there are no controlled studies, open label reports and clinical experience indicate that atypical agents such as quetiapine and clozapine have a limited role in the treatment of chorea. On the other hand, if typical neuroleptics are effective in reduction of chorea, they are often associated with unacceptable side effects such as sedation, acute dystonic reaction, tardive dyskinesia, and parkinsonism. The latter can be a problem in Huntington disease because with progression of the illness there is a tendency for development of rigidity and dystonia (44). Similarly, in hemiballism-hemichorea, chorea suppression on one side of the body may be accompanied by simultaneous development of parkinsonism on the opposite hemibody. Risperidone and olanzapine are atypical antipsychotics with definite antichoreic activity but lesser potential to induce parkinsonism than typical neuroleptics.

There are numerous reports of use of tetrabenazine, which inhibits vesicular monoamine transporter 2 inhibitor (VMAT2) and, thus, acts as a presynaptic dopamine depletor to treat chorea associated with cerebral palsy and other causes (114; Chatterjee and Frucht 2003; 76; 71; 106). Controlled data have confirmed that this agent is indeed efficacious in controlling chorea in Huntington disease (64; 76; 52; 72). Tetrabenazine is now an FDA-approved agent for symptomatic control of chorea in Huntington disease. A review of a large number of patients with chorea of different causes confirms the efficacy and safety of treatment with tetrabenazine (139; 71). Another VMAT2 inhibitor, deutetrabenazine, has been found to be efficacious in the treatment of chorea associated with Huntington disease, tardive dyskinesia, and tics associated with Tourette syndrome (65; 71). Also, valbenazine, another VMAT2 inhibitor, was evaluated for the treatment of chorea, tardive dyskinesia, and tics (71; 09). Approved by the U.S. Food and Drug Administration for the treatment of chorea associated with Huntington disease (tetrabenazine, deutetrabenazine) and tardive dyskinesia (valbenazine, deutetrabenazine), these VMAT2 inhibitors are considered the treatment of choice for other choreas (09; 50). An open-label study suggests that aripiprazole has efficacy comparable to tetrabenazine in the control of chorea in Huntington disease, but further studies are required to confirm this observation (18). Even if confirmed, aripiprazole, in contrast to tetrabenazine, carries the risk of tardive dyskinesia. Levodopa may be required in patients with juvenile Huntington disease or in adults with advanced disease and severe rigidity. This drug has also been reported as useful to the management of patients with NKX2-1 mutation (04), but this requires further confirmation.

Nondopaminergic agents may also be effective in the management of chorea. Amantadine is believed to act primarily via a NMDA blocking mechanism. There are a few small, controlled studies of this agent in Huntington disease (97; 116). Although the results are contradictory, the weight of evidence is in favor of a weak antichoreic action in this condition. Valproic acid is widely used in the treatment of chorea in Sydenham chorea. Although a few open-label studies and clinical experience strongly support the efficacy of the drug in this indication, no controlled studies have addressed this issue. Carbamazepine is also rarely used to treat Sydenham chorea (62). First-line immunotherapy consists of intravenous methylprednisolone, IVIg or plasmapheresis, or a combination of these modalities (108; 27; 22; 01). Second-line agents include rituximab or cyclophosphamide. In refractory cases, tocilizumab (an interleukin-6 receptor inhibitor) or bortezomib (a proteasome inhibitor) have been utilized. Latrepirdine, an agent that possibly improves mitochondrial function, has been shown to cause mild improvement of cognition in patients with Huntington disease (78). Subsequent studies, however, were disappointing and the agent is no longer in development.

Surgery to treat chorea is rarely needed. However, this may be the case in a few patients with persistent vascular chorea (arbitrarily defined as duration longer than 1 year) in whom stereotactic surgery such as thalamotomy or posteroventral pallidotomy is effective (21; 29). There are also a few reports describing effectiveness of surgery to treat chorea related to cerebral palsy (87), “senile chorea” (157), and dentatorubral-pallidoluysian atrophy (153). Finally, pallidotomy and pallidal-stimulation have also been used in Huntington disease (36; 107). Although chorea is effectively controlled by these procedures, the relentless progression of Huntington disease leads to a loss of functional improvement (75). There have been several patients with Huntington disease treated with fetal cell implantation in the striatum. Despite a few positive reports, in the majority of cases no improvement has been observed. Autopsy studies have shown that the grafts survive but do not integrate with host striatum (76; 32). With the advent of deep brain stimulation (DBS), there is growing awareness of the beneficial role of this procedure to treat chorea (47). Reports describe its usefulness in the management of selected patients with chorea-acanthocytosis (93). A large series of patients with refractory tardive dyskinesia that included chorea underwent GPi deep brain stimulation with sustained benefit (130). In the past few years, several groups have reported effective use of deep brain stimulation to treat chorea in chorea-acanthocytosis (152; 156).

Ongoing clinical trials aim to use antisense oligonucleotide technology to lower Huntingtin levels in Huntington disease based on the preclinical findings that lowering Huntingtin in the brain is correlated with the reduction of Huntington disease-like symptoms in rodent models (100; 25). There are mainly 3 Huntingtin level lowering strategies. First one is genome editing by interrupting the CAG repeat expansion, which can potentially delay the onset of disease. Second strategy aims at the protein level by interrupting axonal transport of Huntingtin and induction of autophagy to inhibit the accumulation of mutant Huntingtin protein. Although the first two strategies are still in preclinical phase, phase III clinical trials are ongoing to investigate gene expression modification strategies, which aim to inhibit the generation of Huntingtin protein.

References

01: Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 2021;92(7):757-68. PMID 33649022
02: Albin RL, Young AB, Penney JB. The functional anatomy of the basal ganglia. Trends Neurosci 1989;10:366-75. PMID 2479133
03: Armstrong MJ, Shah BB, Chen R, et al. Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. Mov Disord 2011;26:2296-7. PMID 21714005
04: Asmus F, Horber V, Pohlenz J, et al. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa. Neurology 2005;64:1952-4. PMID 15955952
05: Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna) 2013;120(11):1579-89. PMID 23580159
06: Baizabal-Carvallo JF, Cardoso F. Chorea in children: etiology, diagnostic approach and management. J Neural Transm (Vienna) 2020;127(10):1323-42. PMID 32776155
07: Balint B, Bhatia KP. Stiff person syndrome and other immune-mediated movement disorders - new insights. Curr Opin Neurol 2016;29(4):496-506. PMID 27262149
08: Bartzokis G, Beckson M, Wirshing DA, et al. Choreoathetoid movements in cocaine dependence. Biol Psychiatry 1999;45:1630-5. PMID 10376125
09: Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother 2018;18(1):51-63. PMID 29120264
10: Beato R, Maia DP, Teixeira AL Jr, Cardoso F. Executive functioning in adult patients with Sydenham's chorea. Mov Disord 2010;25:853-7. PMID 20461802
11: Beier K, Pratt DP. Sydenham chorea. In: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing, 2021.
12: Ben-Pazi H, Sadan O, Offen D. Striatal microinjection of Sydenham chorea antibodies: using a rat model to examine the dopamine hypothesis. J Mol Neurosci. 2012;46:162-6. PMID 21647711
13: Betté S, Moore H. Generalized chorea and JAK2V617F mutation-positive myeloproliferative disorders. Mov Disord Clin Pract 2020;7(4):462-3. PMID 32373666
14: Bhidayasiri R, Truong D. Chorea and related disorders. Postgrad Med J 2004;80(947):527-34. PMID 15356354
15: Bohlega SA, Abou-Al-Shaar H, AlDakheel A, et al. Autosomal recessive ADCY5-Related dystonia and myoclonus: Expanding the genetic spectrum of ADCY5-Related movement disorders. Parkinsonism Relat Disord 2019;64:145-9. PMID 30975617
16: Bohrer S, De La Villeon G, Carneiro M, et al. Acute-onset chorea, dystonia, and cardiac fibroelastoma in a child: a paraneoplastic association. Mov Disord 2013;28(2):250-2. PMID 23238994
17: Brimberg L, Benhar I, Mascaro-Blanco A, et al. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology 2012;37(9):2076-87. PMID 22534626
18: Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24(1):126-9. PMID 19170197
19: Carapito R, Paul N, Untrau M, et al. A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia. Mov Disord 2015;30(3):423-7. PMID 25545163
20: Cardoso F. Chorea gravidarum. Arch Neurol 2002;59(5):868-70. PMID 12020275
21: Cardoso F, Jankovic J, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery 1995;36:501-7. PMID 7753350
22: Cardoso F, Maia D, Cunningham MC, Valenca G. Treatment of Sydenham chorea with corticosteroids. Mov Disord 2003;18:1374-7. PMID 14639684
23: Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol 2006;5:589-602. PMID 16781989
24: Carecchio M, Mencacci NE, Iodice A, et al. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord 2017;41:37-43. PMID 28511835
25: Caron NS, Banos R, Yanick C, et al. Mutant Huntingtin is cleared from the brain via active mechanisms in Huntington disease. J Neurosci 2021;41(4):780-96. PMID 33310753
26: Cavalcanti A, Hilario MO, dos Santos FH, Bolognani SA, Bueno OF, Len CA. Subtle cognitive deficits in adults with a previous history of Sydenham's chorea during childhood. Arthritis Care Res (Hoboken) 2010;62(8):1065-71. PMID 20235195
27: Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27. PMID 11953980
28: Chalia M, Subramanian T. Type 2 diabetes presenting with persistent chorea. JAMA Neurol 2019;76(3):366-7. PMID 30575849
29: Choi SJ, Lee SW, Kim MC, et al. Posteroventral pallidotomy in medically intractable postapoplectic monochorea: case report. Surg Neurol 2003;59:486-90. PMID 12826351
30: Chung SJ, Im JH, Lee MC, Kim JS. Hemichorea after stroke: clinical-radiological correlation. J Neurol 2004;251(6):725-9. PMID 15311349
31: Church AJ, Cardoso F, Dale RC, Lees AJ, Thompson EJ, Giovannoni G. Anti-basal ganglia antibodies in acute and persistent Sydenham s chorea. Neurology 2002;59(2):227-31. PMID 12136062
32: Clelland CD, Barker RA, Watts C. Cell therapy in Huntington disease. Neurosurg Focus 2008;24(3-4):E9. PMID 18341412
33: Crealey M, Allen NM, Webb D, et al. Sydenham's chorea: not gone but perhaps forgotten. Arch Dis Child 2015;100(12):1160-2. PMID 26374756
34: Crossman AR. Functional anatomy of movement disorders. J Anat 2000;196(4):519-25. PMID 10923984
35: Croteau D, Owainati A, Dalmau J, Rogers LR. Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology 2001;57(4):719-22. PMID 11524490
36: Cubo E, Shannon KM, Penn RD, Kroin JS. Internal globus pallidotomy in dystonia secondary to Huntington's disease. Mov Disord 2000;15:1248-51. PMID 11104214
37: Cui R, You H, Niu N, Li F. FDG PET brain scan demonstrated glucose hypometabolism of bilateral caudate nuclei and putamina in a patient with chorea-acanthocytosis. Clin Nucl Med 2015;40(12):979-80. PMID 26359566
38: Cunningham MW, Cox CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol (Oxf) 2016;216(1):90-100. PMID 26454143
39: Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009;11(2):102-10. PMID 19210912
40: Dale RC, Singh H, Troedson C, Pillai S, Gaikiwari S, Kozlowska K. A prospective study of acute movement disorders in children. Dev Med Child Neurol 2010;52:739-48. PMID 20163436
41: Dale RC, Yin K, Ding A, et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol. 2011;53:522-8. PMID 21574989
42: de Gusmäo CM, Berkowitz AL, Hung AY, Westover MB. Cerebrospinal fluid shunt-induced chorea: case report and review of the literature on shunt-related movement disorders. Pract Neurol 2015;15(1):42-4. PMID 24997172
43: Dean SL, Singer HS. Treatment of Sydenham’s chorea: a review of the current evidence. Tremor Other Hyperkinet Mov 2017;7:456. PMID 28589057
44: Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat 2004;27:143-64. PMID 15183201
45: Devos D, Vuillaume I, de Becdelievre A, et al. New syndromic form of benign hereditary chorea is associated with a deletion of TITF-1 and PAX-9 contiguous genes. Mov Disord 2006;21:2237-40. PMID 17044090
46: Doyle F, Cardoso F, Lopes L, et al. Infusion of Sydenham's chorea antibodies in striatum with up-regulated dopaminergic receptors: a pilot study to investigate the potential of SC antibodies to increase dopaminergic activity. Neurosci Lett 2012;15;523(2):186-9. PMID 22781496
47: Edwards TC, Zrinzo L, Limousin P, Foltynie T. Deep brain stimulation in the treatment of chorea. Mov Disord 2012;27(3):357-63. PMID 21997283
48: Ellul MA, Wood G, Tooren HVD, Easton A, Babu A, Michael BD. Update on the diagnosis and management of autoimmune encephalitis. Clin Med (Lond) 2020;20(4):389-92. PMID 32675144
49: Fasano A, Di Bonaventura C, Bove F, et al. Movement disorders phenomenology in focal motor seizures. Parkinsonism Relat Disord. 2019;61:161-165. PMID 30361137
50: Feinstein E, Walker R. An update on the treatment of chorea. Curr Treat Options Neurol 2018;20(10):44. PMID 30255459
51: Ferrara AM, De Michele G, Salvatore E, et al. A novel NKX2.1 mutation in a family with hypothyroidism and benign hereditary chorea. Thyroid 2008;18(9):1005-9. PMID 18788921
52: Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs 2010;70(5):561-71. PMID 20329804
53: Gaig C, Compta Y, Heidbreder A, et al. Frequency and characterization of movement disorders in Anti-IgLON5 disease. Neurology 2021;97(14):1367-81. PMID 34380749
54: Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017;88(18):1736-43. PMID 28381508
55: Gao L, Liu A, Zhan S, et al. Clinical characterization of autoimmune LGI1 antibody limbic encephalitis. Epilepsy Behav 2016;56:165-9. PMID 26896820
56: Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 2010;67(3):330-5. PMID 20212230
57: Glik A, Vuillaume I, Devos D, Inzelberg R. Psychosis, short stature in benign hereditary chorea: a novel thyroid transcription factor-1 mutation. Mov Disord 2008;23(12):1744-7. PMID 18661567
58: Gras D, Jonard L, Roze E, et al. Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene. J Neurol Neurosurg Psychiatry 2012;83(10):956-62. PMID 22832740
59: Haan J, Kremer HP, Padberg GW. Paroxysmal choreoathetosis as presenting symptom of diabetes mellitus. J Neurol Neurosurg Psychiatry 1989;52(1):133. PMID 2709027
60: Hanajima R, Ugawa Y, Terao Y, et al. Intracortical inhibition of the motor cortex is normal in chorea. J Neurol Neurosurg Psychiatry 1999;66:783-6. PMID 10329756
61: Harsanyi E, Moreira J, Kummer A, Meira ZM, Cardoso F, Teixeira AL. Language impairment in adolescents with Sydenham chorea. Pediatr Neurol 2015;53(5):412-6. PMID 26296451
62: Hernandez-Latorre MA, Roig-Quilis M. The efficiency of carbamazepine in a case of post-streptococcal hemichorea. Rev Neurol (Paris) 2003;37:322-6. PMID 14533107
63: Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumor type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80(4):412-6. PMID 18931014
64: Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-72. PMID 16476934
65: Huntington Study Group, Frank S, Testa CM, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 2016;316(1):40-50. PMID 27380342
66: Ignarro RS, Vieira AS, Sartori CR, Langone F, Rogerio F, Parada CA. JAK2 inhibition is neuroprotective and reduces astrogliosis after quinolinic acid striatal lesion in adult mice. J Chem Neuroanat 2013;48-49:14-22. PMID 23403094
67: Inzelberg R, Weinberger M, Gak E. Benign hereditary chorea: An update. Parkinsonism Relat Disord 2011;17(5):301-7. PMID 21292530
68: Iodice A, Carecchio M, Zorzi G, et al. Restless Legs syndrome in NKX2-1-related chorea: an expansion of the disease spectrum. Brain Dev 2019;41(3):250-6. PMID 30352709
69: Itoh H, Shibata K, Nitta E, Takamori M. Hemiballism-hemichorea from marked hypotension during spinal anesthesia. Acta Anaesthesiol Scand 1998;42:133-5. PMID 9527738
70: Jain KK, Bradley WG. Drug-induced movement disorders. Jain KK, Bradley WG, editors. Drug induced neurological disorders. Seattle: Hogrefe & Huber, 2001:171-209.
71: Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 2016;17(18):2461-70. PMID 27819145
72: Jankovic J, Roos RA. Chorea associated with Huntington's disease: to treat or not to treat? Mov Disord 2014;29(11):1414-8. PMID 25156927
73: Kanazawa I. Dentatorubral-pallidoluysian atrophy or Naito-Oyanagi disease. Neurogenetics 1998;2(1):1-17. PMID 9933295
74: Kanazawa I, Murata M, Kimura M. Roles of dopamine and its receptors in generation of choreic movements. Adv Neurol 1993;60:107-12. PMID 8093572
75: Kang GA, Heath S, Rothlind J, Starr PA. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease. J Neurol Neurosurg Psychiatry 2011;82(3):272-7. PMID 20974647
76: Keene CD, Sonnen JA, Swanson PD, et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007;68(24):2093-8. PMID 17562830
77: Khedr EM, Ahmed MA, Ali AM, Badry R, Rothwell JC. Changes in motor cortical excitability in patients with Sydenham's chorea. Mov Disord 2015;30(2):259-62. PMID 24909435
78: Kieburtz K, McDermott MP, Voss TS, et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 2010;67(2):154-60. PMID 20142523
79: Kiechl-Kohlendorfer U, Ellemuter H, Kiechl S. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics 1999;30:96-8. PMID 10401693
80: Kim YJ, Kim SJ, Kim J, et al. Chorea due to diabetic hyperglycemia and uremia: distinct clinical and imaging features. Mov Disord 2015;30(3):419-22. PMID 25649292
81: Kinboshi M, Inoue M, Kojima Y, et al. An elderly case of moyamoya disease presenting with hemichorea. Rinsho Shinkeigaku. 2012;52:25-9. PMID 22260975
82: Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. J Immunol 2007;178(11):7412-21. PMID 17513792
83: Kleiner-Fisman G, Lang AE. Benign hereditary chorea revisited: a journey to understanding. Mov Disord 2007;22(16):2297-305. PMID 17702033
84: Kleiner-Fisman G, Rogaeva E, Halliday W, et al. Benign hereditary chorea: clinical, genetic, and pathological findings. Ann Neurol 2003;54:244-7. PMID 12891678
85: Konishi T, Kono S, Fujimoto M, et al. Benign hereditary chorea: dopaminergic brain imaging in patients with a novel intronic NKX2.1 gene mutation. J Neurol 2013;260(1):207-13. PMID 22825795
86: Kranick SM, Mowry EM, Colcher A, Horn S, Golbe LI. Movement disorders and pregnancy: a review of the literature. Mov Disord 2010;25(6):665-71. PMID 20437535
87: Krauss JK, Loher TJ, Weigel R, Capelle HH, Weber S, Burgunder JM. Chronic stimulation of the globus pallidus internus for treatment of non-DYT1 generalized dystonia and choreoathetosis: 2-year follow up. J Neurosurg 2003;98:785-92. PMID 12691403
88: Kumar H, Masiowski P, Jog M. Chorea in the elderly with mutation positive polycythemia vera: a case report. Can J Neurol Sci 2009;36:370-2. PMID 19534341
89: Kyle K, Bordelon Y, Venna N, Linnoila J. Autoimmune and paraneoplastic chorea: a review of the literature. Front Neurol 2022;13:829076. PMID 35370928
90: Larrosa D, Ramon C, Santamarta E, Zeidan N, Pascual J. Hemichorea secondary to contralateral pontine haemorrhage. Parkinsonism Relat Disord 2013;19(2):271-2. PMID 22795480
91: Lasker AG, Zee DS. Ocular motor abnormalities in Huntington’s disease. Vision Res 1997;37(24):3639-45. PMID 9425536
92: Lee CC, Pan DH, Chung WY, et al. Brainstem cavernous malformations: the role of Gamma Knife surgery. J Neurosurg 2012;117(Suppl):164-9. PMID 23205805
93: Lee JH, Cho WH, Cha SH, Kang DW. Globus pallidus interna deep brain stimulation for chorea-acanthocytosis. J Korean Neurosurg Soc 2015;57(2):143-6. PMID 25733999
94: Lee MS, Marsden CD. Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord 1994;9(5):493-507. PMID 7990845
95: Lin JJ. Generalized chorea in the syndrome of acute bilateral basal ganglia lesions in patients with diabetic uremia. J Clin Neurosci. 2011;18:1266-8. PMID 21752650
96: Lin JJ, Chang MK. Hemiballism-hemichorea and non-ketotic hyperglycaemia. J Neurol Neurosurg Psychiatry 1994;57(6):748-50. PMID 8006661
97: Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003;60:1995-7. PMID 12821751
98: Madeja M, Kurlemann G. Ceasing of movement-disorder attacks immediately after the onset of pregnancy: possible effect of human chorionic gonadotropin. Lancet 1999;354:745. PMID 10475194
99: Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12. PMID 8139601
100: Marxreiter F, Stemick J, Kohl Z. Huntingtin lowering strategies. Int J Mol Sci 2020;21(6):2146. PMID 32245050
101: McCullar F, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA 1975;231:62-4. PMID 1243570
102: McNeill A, Chinnery PF. Neuroferritinopathy: update on clinical features and pathogenesis. Curr Drug Targets 2012;13(9):1200-3. PMID 22515742
103: Medlock MD, Cruse RS, Winek SJ, et al. A 10-year experience with postpump chorea. Ann Neurol 1993;34:820-6. PMID 8250531
104: Mink JW. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol 2003;60:1365-8. PMID 14568805
105: Molina-Calavita M, Barnat M, Elias S, Aparicio E, Piel M, Humbert S. Mutant huntingtin affects cortical progenitor cell division and development of the mouse neocortex. J Neurosci 2014;34(30):10034-40. PMID 25057205
106: Monbaliu E, Himmelmann K, Lin JP, et al. Clinical presentation and management of dyskinetic cerebral palsy. Lancet Neurol 2017;16(9):741-9. PMID 28816119
107: Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 2004;56:290-4. PMID 15293283
108: Navarrete MG, Brey RL. Neuropsychiatric systemic lupus erythematosus. Curr Treat Options Neurol 2000;2:473-85. PMID 11096772
109: Niccolini F, Mencacci NE, Yousaf T, et al. PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. Mov Disord 2018;33(12):1961-5. PMID 30345538
110: Noda K, Tosaka Y, Ishiguro Y, et al. Delayed chorea after recovery from severe akinetic-rigid parkinsonism caused by extrapontine myelinolysis. J Neurol Sci 2015;358(1-2):498-500. PMID 26384614
111: Noonan S, Zurynski YA, Currie BJ, et al. A national prospective surveillance study of acute rheumatic fever in Australian children. Pediatr Infect Dis J 2013;32(1):e26-32. PMID 22926211
112: Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Arbizu J, Gimenez-Amaya JM. The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol Sci 2002;17:51-5. PMID 11909992
113: O'Brien CF, Kurlan R. Movement disorders and pregnancy. In: Goldstein PJ, Stern BJ, editors. Neurological Disorders of Pregnancy. 2nd ed. Mount Kisco: Futura Publ, 1992:181-203.
114: Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25:300-2. PMID 12469001
115: Ossterveer DM, Overweg-Plandsoen W, Roos R. Sydenham's chorea: a practical overview of the current literature. Pediatr Neurol 2010;43:1-6. PMID 20682195
116: O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60:996-8. PMID 12873857
117: O'Toole O, Lennon VA, Ahlskog JE, et al. Autoimmune chorea in adults. Neurology 2013;80(12):1133-44. PMID 23427325
118: Park KW, Choi N, Ryu HS, Kim HJ, Lee CS, Chung SJ. Post-pump chorea and progressive supranuclear palsy-like syndrome following major cardiac surgery. Mov Disord Clin Pract 2019;7(1):78-82. PMID 31970215
119: Parnes M, Bashir H, Jankovic J. Is benign hereditary chorea really benign? Brain-lung-thyroid syndrome caused by NKX2-1 mutations. Mov Disord Clin Pract 2018;6(1):34-9. PMID 30746413
120: Patankar AP. Hemi-chorea: an unusual presentation of brainstem glioma. Br J Neurosurg 2013;27(2):256-8. PMID 23171149
121: Patel NJ, Jankovic J. NKX2-1-related disorders. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews® [Internet]. Seattle: University of Washington, 2016.
122: Patrick SJ, Snelling LK, Ment LR. Infantile chorea following abrupt withdrawal of diazepam and pentobarbital therapy. J Toxicol Clin Toxicol 1993;1:127-32. PMID 8433409
123: Peall KJ, Lumsden D, Kneen R, et al. Benign hereditary chorea related to NKX2.1: expansion of the genotypic and phenotypic spectrum. Dev Med Child Neurol 2014;56(7):642-8. PMID 24171694
124: Peluso S, Antenora A, De Rosa A, et al. Antiphospholipid-related chorea. Front Neurol 2012;3:150. PMID 23097646
125: Penney J, Young A. Striatal inhomogeneities and basal ganglia function. Mov Disord 1986;1:3-15. PMID 2848190
126: Piccolo I, Causarano R, Sterzi R, et al. Chorea in patients with AIDS. Acta Neurol Scand 1999;100:332-6. PMID 10536922
127: Piccolo I, Defanti CA, Soliveri P, Volonte MA, Cislaghi, Girotte F. Cause and course in a series of patients with sporadic chorea. J Neurol 2003;250:429-35. PMID 12700907
128: Piccolo I, Sterzi R, Thiella G. Chorea in hyperglycemia. Diabetes Care 1998;21(10):1777. PMID 9773750
129: Poewe W, Wenning GL. Chorea and ballism. In: Tolosa E, Koller WC, Gershanik OS, editors. Differential diagnosis and treatment of movement disorders. Boston: Butterworth-Heinemann, 1998:77-88.
130: Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 2016;86(7):651-9. PMID 26791148
131: Reiner P, Galanaud D, Leroux G, et al. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Mov Disord. 2011;26:2422-7. PMID 21755538
132: Saft C, Reber D, Streuer M, Andrich J. Post pump chorea in a 77-year-old male. Neurol Sci. 2011;32:699-701. PMID 21499730
133: Sajjad Baig S, Strong M, Quarrell OW. Global prevalence of Huntington’s disease: a systemic review and discussion. Neurodegener Dis Manag 2016;6(4):331-43. PMID 27507223
134: Salpietro V, Perez-Dueñas B, Nakashima K, et al. A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea. Mov Disord 2018;33(3):482-8. PMID 29392776
135: Sato K, Hida A, Kameyama M, Morooka M, Takeuchi S. Reduced 123I ioflupane binding in bilateral diabetic chorea: findings with 18F FDG PET, 99mTc ECD SPECT, and 123I MIBG scintigraphy. Clin Nucl Med 2016;41(6):481-2. PMID 26975011
136: Sawlani K, Katirji B. Peripheral nerve and hyperexcitability syndromes. Continuum 2017;23(5):1437-50. PMID 28968370
137: Schneider SA, Hennig A, Martino D. Relationship between COVID-19 and movement disorders: a narrative review. Eur J Neurol 2022;29(4):1243-53. PMID 34918437
138: Schulman J, Stern H. Low utilization of prenatal and pre-implantation genetic diagnosis in Huntington disease–risk discounting in preventive genetics. Clin Gen 2015;88(3):220-3. PMID 25307798
139: Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington's and other diseases. Tremor Other Hyperkinet Mov (N Y) 2013;3. PMID 24255799
140: Siesling S, Vegter-van de Vlis M, Losekoot M, et al. Family history and DNA analysis in patients with suspected Huntington s disease. J Neurol Neurosurg Psychiatry 2000;69(1):54-9. PMID 10864604
141: Smith MT, Lester-Smith D, Zurynski Y, Noonan S, Carapetis JR, Elliott EJ. Persistence of acute rheumatic fever in a tertiary children's hospital. J Paediatr Child Health 2011;47(4):198-203. PMID 21199062
142: Srinivasan S, Lok AW. Valproate-induced reversible hemichorea. Mov Disord 2010;25(10):1511-2. PMID 20629154
143: Synofzik M, Srulijes K, Godau J, Berg D, Schvls L. Characterizing POLG ataxia: clinics, electrophysiology and imaging. Cerebellum 2012;11(4):1002-11. PMID 22528963
144: Teixeira AL, Bretas TL, Kummer A, et al. Serum levels of brain-derived neurotrophic factor in Sydenham's chorea. Neurol Sci 2010;31(3):399-401. PMID 20112124
145: Thompson PD, Berardelli A, Rothwell JC, et al. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 1988;111:223-44. PMID 2967729
146: Valldeoriola F. Movement disorders of autoimmune origin. J Neurol 1999;246:423-31. PMID 10431765
147: van de Velde K, Cras P, Helsen G. Acute chorea caused by valproate in an elderly. Acta Neurol Belg. 2011;111:220-1 PMID 22141287
148: Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002;51:625-30. PMID 12112110
149: Vigliani MC, Honnorat J, Antoine JC, et al. Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. J Neurol. 2011;258:2058-68. PMID 21559939
150: Walker RH, Miranda M, Jung HH, Danek A. Life expectancy and mortality in chorea-acanthocytosis and McLeod syndrome. Parkinsonism Relat Disord 2019;60:158-61. PMID 30245172
151: Walterfang M, Evans A, Looi JC, et al. The neuropsychiatry of neuroacanthocytosis syndromes. Neurosci Biobehav Rev 2011;35:1275-83. PMID 21237198
152: Wang KL, Hess CW, Xu D, et al. High frequency bilateral globus pallidus interna deep brain stimulation can improve both chorea and dysarthria in chorea-acanthocytosis. Parkinsonism Relat Disord 2019;62:248-50. PMID 30658884
153: Watarai M, Hashimoto T, Yamamoto K, Matsumoto Y, Tada T, Ikeda S. Pallidotomy for severe generalized chorea of juvenile-onset dentatorubral-pallidoluysian atrophy. Neurology 2003;61:1452-4. PMID 14638982
154: Willemsen MA, Breedveld GJ, Wouda S, et al. Brain-Thyroid-Lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr 2005;164:28-30. PMID 15517377
155: Wong PC, Barlow CF, Hickey PR, et al. Factors associated with choreoathetosis after cardiopulmonary bypass in children with congenital heart disease. Circulation 1992;86(5 Suppl):II118-26. PMID 1423989
156: Wu Y, Li H, Zhang C, Sun B, Li D, Wu Y. Subthalamic nucleus deep brain stimulation in two siblings with chorea-acanthocytosis. Neurol Sci 2020;41(6):1623-5. PMID 31938984
157: Yianni J, Nandi D, Bradley K, et al. Senile chorea treated by deep brain stimulation: a clinical, neurophysiological and functional imaging study. Mov Disord 2004;19:597-602. PMID 15133831
158: Zabek M, Sobstyl M, Dzierzecki S, Gorecki W, Jakucinski M. Right hemichorea treated successfully by surgical removal of a left putaminal cavernous angioma. Clin Neurol Neurosurg 2013;115(6):844-6. PMID 23079109
159: Zomorrodi A, Wald ER. Sydenham's chorea in western Pennsylvania. Pediatrics 2006;117:e675-9. PMID 16533893
160: Zuccarelli B, Aalbers B, Grabb P. Hemiballismus as a complication of an intratumoral chemotherapy catheter. J Clin Neurosci 2016;30:129-31. PMID 26964474

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Serena Wong MD

Dr. Wong of St. George's University School of Medicine has no relevant financial relationships to disclose.
See Profile
Robert Fekete MD

Dr. Fekete of New York Medical College received consultation fees from Acadia Pharmaceutical, Acorda, Adamas/Supernus Pharmaceuticals, Amneal/Impax, Kyowa Kirin, Lundbeck Inc., Neurocrine Inc., and Teva Pharmaceutical, Inc.
See Profile

Former Authors

Francisco Cardoso MD PhD
Christopher F O'Brien MD (original author) and Sharin Y Sakurai MD PhD

ICD & OMIM codes

ICD-9: Chorea: 333.5
ICD-10: Chorea, NOS: G25.5
OMIM: Familial benign chorea: 215450

Hereditary benign chorea: #118700

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Chorea

Associated Disorders

CRMP-5 (CV2)
ANNA-1 (Hu)
NMDAR
ANNA-2 (Ri)
CASPR2
- PDE-10A
- SLE
- PAPS
- NMDAR
- GAD-65
- CASPR2
- LGI1
- IgLON5
- Ataxia-telangiectasia
- Ataxia associated with oculomotor apraxia
- Benign hereditary chorea
- C9orf72 expansions
- Dentatorubropallidoluysian degeneration
- Friedreich ataxia
- Glucose transporter deficiency
- Huntington disease
- Huntington disease-like illnesses
- Leigh disease and other mitochondriopathies
- Lesch-Nyhan disease
- McLeod syndrome
- Neuroacanthocytosis
- Neuroferritinopathy
- Pantothenate kinase associated degeneration
- POLG mutation
- Prion disease
- PRRT2 gene mutation
- Spinocerebellar atrophy type 2
- Spinocerebellar atrophy type 3
- Spinocerebellar atrophy type 17
- Tuberous sclerosis
- Xeroderma pigmentosum
- Wilson disease
- Amantadine
- Amphetamine
- Anticonvulsants
- Antihistamine agents
- Carbon monoxide
- CNS stimulants (methylphenidate, pemoline, cyproheptadine)
- Cocaine
- Dopamine agonists
- Dopamine-receptor blockers
- Ethanol
- Levodopa
- Levofloxacin
- Lithium
- Sympathomimetics
- Theophylline
- Tricyclic antidepressants
- Valproic acid
- Withdrawal emergent syndrome
- AIDS related (toxoplasmosis, progressive multifocal leukoencephalopathy, HIV encephalitis)
- Diphtheria
- Scarlet fever
- Whooping cough
- B19 parvovirus
- Herpes-6 virus encephalitis
- Influenza encephalitis
- Japanese encephalitis
- Measles
- Mumps
- HIV
- West Nile River encephalitis
- SARS-CoV-2
- Neurocysticercosis
- Malaria
- Syphilis
- Adrenal insufficiency
- Hyper/hypocalcemia
- Hyper/hypoglycemia
- Hypomagnesemia
- Hypernatremia
- Liver failure
- Uremia
- Polycythemia vera
- Postpump chorea (cardiac surgery)
- Posterior reversible encephalopathy syndrome
- Stroke
- Subdural hematoma
- Anoxic encephalopathy
- Brainstem cavernous malformation
- Brainstem glioma
- Cerebral palsy
- Cerebrospinal fluid shunt-induced
- Extrapontine myelinolysis
- Intratumoral chemotherapy catheter
- Kernicterus
- Multiple sclerosis
- Normal maturation (less than 12 months old)
- Nutritional (eg, B12 deficiency)
- Pontine hemorrhage
- Posttraumatic (brain injury)
- Putaminal cavernous malformation

Differential Diagnosis

autoimmune diseases
metabolic derangement
drugs
Huntington disease
Wilson disease

Also Relevant

Childhood movement disorders
Chorea in childhood
Hemiballism
Huntington disease
Motor control of movement disorders
- Neuroacanthocytosis
- Rating scales of movement disorders
- Sydenham chorea
- Valproic acid
- Wilson disease

Clinical Categories

Movement Disorders

Patient Handouts

Web References

Testing

Alerts and Advisories

FDA approves INGREZZA® (valbenazine) for chorea associated with Huntington disease

Clinical Trials

NIH: Chorea

Chorea …

Chorea

Introduction

Overview

Key points

Clinical manifestations

Presentation and course

Primary chorea

Secondary chorea

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Table 1. Conditions Associated with Chorea

Diagnostic workup

Table 2. Initial Laboratory Investigation of Chorea

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Former Authors

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

Chorea

Introduction

Overview

Key points

Clinical manifestations

Presentation and course

Primary chorea

Secondary chorea

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Table 1. Conditions Associated with Chorea

Diagnostic workup

Table 2. Initial Laboratory Investigation of Chorea

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Former Authors

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

This is an article preview.
Start a Free Account
to access the full version.